Strategic Resource Reallocation Through Focus and Selection
First written in FY2016. 33 of 34 entries say "Restated". Latest entry: FY2026.
57 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「During the current consolidated fiscal year, the pharmaceutical-related business continued to actively conduct information-provision activities centered on core products, with cardiovascular medicine, gastroenterology, obstetrics and gynecology, and psychiatry as its priority areas.」
We continue to concentrate resources on the 4 priority areas and conduct activities centered on core products. - FY2025RestatedAnnual report
「In our core pharmaceutical-related business, we continued to pursue a thorough commitment to stable supply and maintaining appropriate quality, while placing greater emphasis on new drugs and other products.」
The company continues to focus on priority areas and new drugs, and the 25–27 Medium-Term Management Plan calls for strengthening earnings power by maximizing the value of 5 major new drugs and expanding the pipeline through in-licensing. - FY2025-H1RestatedAnnual report
「During the interim consolidated accounting period, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted information-provision activities centered on core products.」
We continue to concentrate resources on the priority areas of cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology, while conducting information-provision activities centered on core products. - FY2024-Q3RestatedAnnual report
「During the first 9 months of the current fiscal year, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted information-provision activities centered on core products.」
We continue to concentrate resources on the 4 priority areas of cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology, while conducting information-provision activities centered on core products. - FY2024-Q2RestatedAnnual report
「During the first six months of the current fiscal year, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted information-provision activities centered on core products.」
We continue to concentrate resources on the 4 priority areas of cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology, while conducting information-provision activities centered on core products. - FY2024-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted information-provision activities centered on core products.」
We continue to concentrate resources on the 4 priority areas of cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology, while conducting information-provision activities centered on core products. - FY2023RestatedAnnual report
「In our core pharmaceutical-related business, we will concentrate resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology,” maintain our position, and work to maximize revenue from new drugs.」
The company continues to concentrate resources on priority areas and specifies cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology as the areas covered. - FY2023-Q3RestatedAnnual report
「During the first 9 months of the current fiscal year, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted activities to provide academic information, centered on core products.」
We continue to concentrate resources on the 4 priority areas of cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology, while conducting activities to provide academic information centered on core products. - FY2023-Q2RestatedAnnual report
「During the first six months of the current fiscal year, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted activities to provide academic information, centered on core products.」
We continue to concentrate resources on the priority areas of cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted activities to provide academic information, centered on core products.」
We continue to concentrate resources on the 4 priority areas of cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology, while conducting activities to provide academic information centered on core products. - FY2022RestatedAnnual report
「In our core pharmaceutical-related business, we will concentrate resources on the priority areas of cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology, maintain our position, and work to maximize revenue from new drugs.」
The 22–24 Medium-Term Management Plan continues the concentration of resources on priority areas and specifies the areas covered. - FY2022-Q3RestatedAnnual report
「Against this backdrop, during the third quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The strategic reallocation of resources through selective focus continued as a key initiative during the third quarter of the current fiscal year. - FY2022-Q2RestatedAnnual report
「“Strategic reallocation of resources through selection and concentration”」
The strategic reallocation of resources through selective focus continued as a key initiative during the second quarter of the current fiscal year. - FY2022-Q1RestatedAnnual report
「We have focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus."」
The strategic reallocation of resources through selective focus continued as a key initiative during the first quarter of the current fiscal year. - FY2021RestatedAnnual report
「Strategic reallocation of resources through selective focus」
The 21-23 Medium-Term Management Plan also continued to present the strategic reallocation of resources through selective focus as a key initiative. - FY2021-Q3RestatedAnnual report
「We have focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus."」
The strategic reallocation of resources through selective focus continued as a key initiative during the third quarter of the current fiscal year. - FY2021-Q2RestatedAnnual report
「We have focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus."」
The strategic reallocation of resources through selective focus continued as a key initiative during the second quarter of the current fiscal year. - FY2021-Q1RestatedAnnual report
「We have focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus."」
The strategic reallocation of resources through selective focus continued as a key initiative during the first quarter of the current fiscal year. - FY2020RestatedAnnual report
「Strategic reallocation of resources through selective focus」
The 20-22 Medium-Term Management Plan also continued to present the strategic reallocation of resources as a key initiative. - FY2020-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2019 through fiscal 2021 announced on 1 April 2019, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure to respond to further changes in the business environment, we would focus on (1) concentrating on new drugs and other products by strengthening sales capabilities, (2) continued investment to build the next generation of core businesses, and (3) the strategic reallocation of resources through selective focus, and we are working to enhance corporate value.」
The strategic reallocation of resources through selective focus continued as a key initiative under the medium-term management plan for fiscal 2019 through fiscal 2021. - FY2020-Q2RestatedAnnual report
「Against this backdrop, during the second quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products by strengthening sales capabilities," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The strategic reallocation of resources through selective focus continued as a key initiative during the second quarter of the current fiscal year. - FY2020-Q1RestatedAnnual report
「Strategic reallocation of resources through selective focus」
It continued as a key initiative under the medium-term management plan for fiscal 2019 through fiscal 2021. - FY2019RestatedAnnual report
「The policy of the Group's 3-year medium-term management plan (the "19-21 Medium-Term Management Plan") is to "bring together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursue selective focus for sustainable growth, and rebuild our earnings structure to respond to further changes in the business environment," and we will continue to focus on the following 3 areas so that we can respond to changes in the business environment: concentrating on new drugs and other products by strengthening sales capabilities, continued investment to build the next generation of core businesses, and the strategic reallocation of resources through selective focus.」
The 19-21 Medium-Term Management Plan also continued to present the strategic reallocation of resources through selective focus as a key initiative. - FY2019-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2018 through fiscal 2020 announced on 2 April 2018, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure to respond to further changes in the business environment, we would focus on (1) concentrating on new drugs and other products by strengthening sales capabilities, (2) continued investment to build the next generation of core businesses, and (3) the strategic reallocation of resources through selective focus, and we are working to enhance corporate value.」
The strategic reallocation of resources through selective focus continued as a key initiative under the medium-term management plan for fiscal 2018 through fiscal 2020. - FY2019-Q2RestatedAnnual report
「Against this backdrop, during the second quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products by strengthening sales capabilities," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The strategic reallocation of resources through selective focus continued as a key initiative during the second quarter of the current fiscal year. - FY2019-Q1RestatedAnnual report
「Strategic reallocation of resources through selective focus」
It continues to be presented as a key initiative under the medium-term management plan for fiscal 2018 through fiscal 2020. - FY2018RestatedAnnual report
「Strategic reallocation of resources through selective focus」
It continues to be presented as one of the key initiatives under the 18-20 Medium-Term Management Plan. - FY2018-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2017 through fiscal 2019 (fiscal 2017 through fiscal 2019 in the Japanese fiscal-year system) announced on 3 April 2017, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) continued investment to build the next generation of core businesses, (2) the strategic reallocation of resources through selective focus, and (3) concentrating on new drugs and other products by strengthening sales capabilities, and we are working to enhance corporate value.」
The strategic reallocation of resources through selective focus continues to be presented as a key initiative of the medium-term management plan. - FY2018-Q2RestatedAnnual report
「In the medium-term management plan for fiscal 2017 through fiscal 2019 (fiscal 2017 through fiscal 2019 in the Japanese fiscal-year system) announced on 3 April 2017, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) continued investment to build the next generation of core businesses, (2) the strategic reallocation of resources through selective focus, and (3) concentrating on new drugs and other products by strengthening sales capabilities, and we are working to enhance corporate value.」
The strategic reallocation of resources under the new medium-term management plan has been reaffirmed as a key initiative. - FY2018-Q1RestatedAnnual report
「In the medium-term management plan for fiscal 2017 through fiscal 2019 (fiscal 2017 through fiscal 2019 in the Japanese fiscal-year system) announced on 3 April 2017, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) continued investment to build the next generation of core businesses, (2) the strategic reallocation of resources through selective focus, and (3) concentrating on new drugs and other products by strengthening sales capabilities, and we are working to enhance corporate value.」
The new medium-term management plan also identifies the strategic reallocation of resources through selective focus as a key initiative. - FY2017-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2016 through fiscal 2018 (fiscal 2016 through fiscal 2018 in the Japanese fiscal-year system) announced on 1 April 2016, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) the strategic reallocation of resources through selective focus, (2) concentrating on new drugs and other products by strengthening sales capabilities, and (3) continued investment to build the next generation of core businesses, and we are working to enhance corporate value.」
The strategic reallocation of resources has been reaffirmed as a key initiative of the medium-term management plan. - FY2017-Q2RestatedAnnual report
「In the medium-term management plan for fiscal 2016 through fiscal 2018 (fiscal 2016 through fiscal 2018 in the Japanese fiscal-year system) announced on 1 April 2016, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) the strategic reallocation of resources through selective focus, (2) concentrating on new drugs and other products by strengthening sales capabilities, and (3) continued investment to build the next generation of core businesses, and we are working to enhance corporate value.」
The strategic reallocation of resources has been reaffirmed as a key initiative of the medium-term management plan. - FY2017-Q1RestatedAnnual report
「In the medium-term management plan for fiscal 2016 through fiscal 2018 (fiscal 2016 through fiscal 2018 in the Japanese fiscal-year system) announced on 1 April 2016, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) the strategic reallocation of resources through selective focus, (2) concentrating on new drugs and other products by strengthening sales capabilities, and (3) continued investment to build the next generation of core businesses, and we are working to enhance corporate value.」
The strategic reallocation of resources is restated as a key initiative of the medium-term management plan. - FY2016First statedAnnual report
「Strategic reallocation of resources through selective focus」
One of the 3 key initiatives beginning in fiscal 2016.